Pharvaris (NASDAQ:PHVS) Insider Peng Lu Sells 300 Shares

Pharvaris N.V. (NASDAQ:PHVS) insider Peng Lu sold 300 shares of Pharvaris stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $34.00, for a total transaction of $10,200.00. Following the completion of the sale, the insider owned 65,631 shares of the company’s stock, valued at approximately $2,231,454. The trade was a 0.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Peng Lu also recently made the following trade(s):

• On Wednesday, April 29th, Peng Lu sold 3,733 shares of Pharvaris stock. The stock was sold at an average price of $30.06, for a total value of $112,213.98.
• On Thursday, April 30th, Peng Lu sold 15,000 shares of Pharvaris stock. The stock was sold at an average price of $30.24, for a total value of $453,600.00.
• On Thursday, April 23rd, Peng Lu sold 100 shares of Pharvaris stock. The shares were sold at an average price of $30.03, for a total transaction of $3,003.00.
• On Wednesday, April 22nd, Peng Lu sold 7,001 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total transaction of $210,380.05.

Pharvaris Price Performance

NASDAQ PHVS opened at $33.19 on Wednesday. The business has a fifty day moving average price of $30.27 and a two-hundred day moving average price of $27.84. The stock has a market capitalization of $2.17 billion, a PE ratio of -10.44 and a beta of -2.35. Pharvaris N.V. has a fifty-two week low of $16.72 and a fifty-two week high of $34.41.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.12. As a group, sell-side analysts expect that Pharvaris N.V. will post -3.22 earnings per share for the current year.

Institutional Trading of Pharvaris

Several institutional investors and hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP purchased a new stake in Pharvaris in the 3rd quarter valued at $43,282,000. Paradigm Biocapital Advisors LP boosted its holdings in Pharvaris by 72.7% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock worth $45,796,000 after acquiring an additional 772,583 shares during the last quarter. Balyasny Asset Management L.P. purchased a new position in Pharvaris during the 3rd quarter worth $15,613,000. Commodore Capital LP grew its stake in shares of Pharvaris by 26.5% in the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after acquiring an additional 507,043 shares in the last quarter. Finally, General Atlantic L.P. grew its stake in shares of Pharvaris by 6.6% in the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after acquiring an additional 500,000 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on PHVS. Wall Street Zen upgraded shares of Pharvaris from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. Citigroup restated a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. Wedbush raised their price objective on shares of Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. Finally, UBS Group set a $74.00 target price on Pharvaris in a research report on Wednesday, May 13th. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Pharvaris has a consensus rating of “Moderate Buy” and an average price target of $49.18.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.